What Medicare Advantage Plans Must Do to Prepare for 2026 Audits

Why It Matters

The new audit regime can trigger contract‑wide payment adjustments and hefty penalties, making RADV compliance a critical financial and regulatory priority for Medicare Advantage carriers.

Key Takeaways

• Extrapolation from PY 2018 sample can affect entire contract payment
• CMS audit calendar lists PY 2020, 2021, 2023, 2024 initiations in 2026
• V28 model at 100% changes HCC coding, creating new error risks
• Missing signatures, thin notes, and HRA‑only diagnoses drive most invalidations
• 90‑day sprint with governance, mock audits, and appeal playbook cuts risk quickly

Pulse Analysis

The 2026 shift to full V28 payment marks a watershed moment for Medicare Advantage risk‑adjustment. By anchoring payment on the 2024 CMS‑HCC model at 100 percent, CMS eliminates the historical fee‑for‑service adjuster and extends extrapolation from the PY 2018 sample to the entire contract. This change amplifies the financial stakes of each diagnosis entry, turning isolated documentation errors into contract‑wide revenue losses. Plans that fail to align historic coding habits with the new model risk substantial payment clawbacks and heightened enforcement scrutiny.

Operational readiness now hinges on disciplined processes and technology. CMS’s published audit calendar—spanning PY 2020, 2021, 2023 and 2024 initiations—gives insurers a narrow window to validate records before spring audits begin. AI‑driven pre‑screening tools, especially natural‑language processing, can flag missing signatures, mismatched provider types, and unsupported HRA‑only diagnoses early, but human review remains essential for audit‑style validation. A structured 90‑day sprint—establishing governance, running mock RADV samples, cleaning documentation, reconciling encounter data, and building an appeal playbook—delivers rapid risk reduction and creates a repeatable compliance rhythm.

Strategically, the 2026 RADV landscape reshapes financial planning for Medicare Advantage carriers. The DOJ’s $172.3 million settlement with Cigna underscores the enforcement appetite for unsupported diagnoses, while OIG alerts signal that HRA‑derived codes are under intense scrutiny. Plans that embed continuous RADV monitoring, enforce strict e‑signature standards, and retain records for the mandated ten‑year period will safeguard revenue and avoid costly penalties. Investing in robust compliance platforms that provide CMS‑style invalid‑reason checks, audit trails, and SOC 2 Type II controls is no longer optional—it’s a competitive necessity for sustaining profitability in the evolving risk‑adjustment environment.